Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.76 |
| ▸ | CA2 | P00918 | 11/20 | 0.76 |
| ▸ | CA9 | Q16790 | 11/20 | 0.76 |
| ▸ | CA12 | O43570 | 8/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dtp-348 SCHEMBL15312833 | 0.86 | CA1 (1.00) | CA1CA2CA9CA12LMNA | |
| Metronidazole SCHEMBL11482439 | 0.83 | LMNA (0.86) | CA1CA2CA9CA12LMNA | |
| SCHEMBL7948094 | 0.82 | CA1 (0.65) | CA1CA2CA9CA12LMNA | |
| SCHEMBL12369632 | 0.81 | CA1 (0.68) | CA1CA2CA9CA12LMNA | |
| SCHEMBL7941864 | 0.81 | CA1 (0.64) | CA1CA2CA9CA12LMNA | |
| SCHEMBL5332268 | 0.81 | LMNA (0.67) | CA1CA2CA9CA12LMNA | |
| SCHEMBL5258409 | 0.81 | CA1 (0.64) | CA1CA2CA9CA12LMNA | |
| SCHEMBL11518789 | 0.81 | CA1 (0.72) | CA1CA2CA9CA12LMNA | |
| SCHEMBL15597315 | 0.80 | LMNA (0.65) | CA1CA2CA9CA12LMNA | |
| SCHEMBL29196833 | 0.80 | CA1 (0.67) | CA1CA2CA9CA12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150849-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO- CLINIC" (NL) | 2015-06-04 | — | — | US | disclosed |
| US-8980932-B2 | Cancer targeting using carbonic anhydrase isoform IX inhibitors | Stichting Maastricht Radiation Oncology “Maastro-Clinic” (NL) | 2015-03-17 | — | — | US | disclosed |
| CN-103443083-A | Cancer Targeting Using Carbonic Anhydrase Isoenzyme IX Inhibitors | STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC | 2013-12-11 | — | — | CN | disclosed |
| US-20130274305-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | Supuran, Claudiu (IT) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150849-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | CA9, HIF1AN, CA4 | CA1 9/4885CA2 5/4885CA9 1/4885 |
| US-20130274305-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | CA9, HIF1AN, CA4 | CA1 9/4885CA2 5/4885CA9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.